

**NITROSATED AND NITROSYLATED  
PHOSPHODIESTERASE INHIBITOR  
COMPOUNDS, COMPOSITIONS AND THEIR USES**

**BACKGROUND OF THE INVENTION**

This invention generally relates to pharmaceuticals and more specifically to a method and compositions for inducing penile erections in human males suffering from impotence, a method and compositions for treating female sexual dysfunction, and a method and compositions for treating human anal disease resulting from excessive anal sphincter tone.

Male erectile dysfunction is a widespread disorder that is thought to affect about ten to fifteen percent of the adult men. In a similar fashion, it is now beginning to be recognized that female sexual dysfunction is also a significant problem among adult women. With the male cases, a number of causes of these insufficiencies, in addition to anatomical deficiencies of the penis that preclude an erection sufficient for vaginal penetration, have been identified. Causes of erectile dysfunction can be categorized as psychogenic, neurogenic, endocrinologic, drug-induced, or vasculogenic and in any male suffering from erectile dysfunction there may be more than one cause. Female sexual

dysfunction may also be categorized as psychogenic, neurogenic, endocrinologic, drug-induced, or vasculogenic and a female with one or more of these etiologies may also experience a lack of satisfaction in sexual relations.

Psychogenic impotence is often the result of anxiety or depression, with no apparent somatic or organic impairment. Neurogenic impotence may arise from, for example, surgery or a pelvic injury, involving the nervous system affecting the penis or vagina. Sexual dysfunction which is in endocrinologic in origin is most often associated with the disorders hypo- or hypergonadotropic hypogonadism and hyperprolactinemia in the male and decreases in estrogens in the female.

Vasculogenic sexual dysfunction is thought to be the most frequent cause of sexual dysfunction accounting for approximately fifty percent of all cases of organic sexual dysfunction. In these cases, the erectile dysfunction may be attributed to alterations in the flow of blood to and from the penis while in the female cases vaginal engorgement insufficiency and clitoral erectile insufficiency may be attributed to alterations in blood flow to the vagina and clitoris respectively. Atherosclerotic or traumatic arterial occlusive disease to the arteries which supply blood to the penis can lead to a decrease in the rigidity of the erect penis as well as increase the time to achieving maximal erection. In an analogous fashion, disease which impairs blood flow to the hypogastric-vaginal/clitoral arterial bed may lead to vaginal engorgement insufficiency and clitoral erectile insufficiency. In still other cases, there is an inability to retain blood in the penis or clitoris such that sufficient pressure for an erection can be neither obtained nor maintained.

There is also a high incidence of erectile insufficiency among male diabetics, particularly those with insulin-dependent diabetes mellitus. Erectile dysfunction in male diabetics is often classified as "diabetogenic," although the underlying dysfunction is usually neurogenic and/or vasculogenic. About half of diabetic males suffer from erectile insufficiency, and about half of the cases of neurogenic impotence are in diabetics. A significant population of female diabetics also exhibit symptoms of sexual dysfunction, especially those with complications directly attributed to the disease.

Sexual dysfunction in both males and females is sometimes a side effect of certain drugs, such as beta-antagonists that are administered to reduce blood pressure in persons suffering from hypertension, or drugs administered to treat depression or anxiety. Excessive alcohol consumption has also been linked to sexual dysfunction. These forms of sexual dysfunction may be regarded as iatrogenic sexual dysfunction.

A number of methods to treat sexual dysfunction are available. These treatments include pharmacological treatments, surgery and, in cases of psychogenic dysfunction, psychological counseling is sometimes effective. Psychogenic sexual dysfunction often can be cured by counseling. Insufficiency due to excessive alcohol consumption is sometimes cured by reducing or eliminating such consumption.

In the rare cases in males, where the insufficiency is untreatable because of venous leakage, surgery can usually be employed to repair the venous lesion and thereby either cure the insufficiency or, if there remains an erectile insufficiency after repair of the venous lesion, render the insufficiency amenable to treatment by pharmacological methods. Also, penile implants, which provide a mechanic means to produce an erection sufficient for vaginal penetration, are widely used to treat impotence. In recent years, implants have been employed, especially in cases where pharmacological intervention is ineffective. Such cases are usually associated with severe forms of vasculogenic impotence. Treatment of impotence with penile implants, however, entails serious disadvantages. Such treatment requires surgery and necessitates total destruction of the erectile tissues of the penis, forever precluding normal erection.

In the male population, pharmacological methods of treatment are also available. Such methods, however, have not proven to be highly satisfactory or without potentially severe side-effects. Papaverine is now widely used to treat impotence, although papaverine is ineffective in overcoming impotence due, at least in part, to severe atherosclerosis. Papaverine is effective in cases where the dysfunction is psychogenic or neurogenic and severe atherosclerosis is not involved. Injection of papaverine, a phosphodiesterase inhibitor and a smooth muscle relaxant, or phenoxybenzamine, a non-specific  $\alpha$ -adrenergic antagonist and hypotensive, into a corpus cavernosum has been found to cause an erection sufficient for vaginal penetration however, these treatments are not without the serious and often painful side effect of priapism. Also, in cases

where severe atherosclerosis is not a cause of the dysfunction, intracavernosal injection of phentolamine, an  $\alpha$ -adrenergic-antagonist, has been shown to produce an erection sufficient for vaginal penetration, however, the resulting erection is one of significantly shorter duration than that induced by intracavernosal injection of papaverine or phenoxylbenzamine. Thus, often times the erection is of such short duration that satisfactory sexual relations are difficult or impossible. As an alternative or, in some cases an adjunct to phosphodiesterase inhibition or  $\alpha$ -adrenergic blockade for the treatment of erectile dysfunction, prostaglandin E1 (PGE1) has been administered via intracavernosal injection. A major side effect frequently associated intracorpally delivered PGE1 is penile pain and burning. Thus, there is a need for methods to induce and maintain a penile erection for a sufficient duration that satisfactory sexual relations are possible without also producing the undesirable side effects of those agents currently used. With regard to female sexual dysfunction, no pharmacological strategies have been yet devised for effective treatment.

A number of anorectal diseases involve excessive anal sphincter tone. For example, anal fissures as well as acutely thrombosed external hemorrhoids are normally accompanied by severe anal pain. Classical treatment of these conditions has usually involved surgery, however, in the treatment of more severe cases, surgical intervention is not without adverse side effects usually involving permanent sphincter defects and subsequent continence disturbances. Recently, nitric oxide has been implicated as the chemical messenger mediating relaxation of the internal anal sphincter. The local application of the exogenous nitric oxide (NO) donors nitroglycerin or isosorbide dinitrate has been reported to improve the symptoms and, in the case of anal fissure, facilitate the healing process. These treatments have not been without the production of undesired systemic side effects the most prevalent of which is headache. Thus, there is a need for methods to treat human anal disease involving excessive anal sphincter tone without also producing the undesirable side effects of those agents currently used.

Nitric oxide has been shown to mediate a number of actions including the bactericidal and tumoricidal actions of macrophages and blood vessel relaxation of endothelial cells. NO, and NO donors have also been implicated as mediators of nonvascular smooth muscle relaxation. This effect includes the dilation of the corpus cavernosum smooth muscle, an event involved in the penile and clitoral erection

processes and the relaxation of the anal sphincter, an event necessary for normal defecation as well as an improvement in the symptoms of pain associated with many anal diseases. However, the effects of modified of phosphodiesterase inhibitors which are directly or indirectly linked with a nitric oxide adduct have not been investigated.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220

## SUMMARY OF THE INVENTION

In the process of arriving at the present invention it was recognized that the risk of toxicities and adverse effects that are associated with high doses of phosphodiesterase inhibitors can be avoided by the use of such phosphodiesterase inhibitors when nitrosated or nitrosylated. Such toxicities and adverse effects include hypotension, syncope, as well as priapism. The smooth muscle relaxant properties of phosphodiesterase inhibitors and of compounds that donate, release or transfer nitrogen monoxide work together to permit the same efficacy with lower doses of the phosphodiesterase inhibitors.

Accordingly, in one aspect the invention provides novel nitrosated and nitrosylated phosphodiesterase inhibitors ( $\text{NO}_n$ -PDE inhibitor) wherein  $n$  is 1 or 2. The phosphodiesterase inhibitor can be nitrosylated or nitrosated through sites such as oxygen (hydroxyl condensation), sulfur (sulfhydryl condensation), carbon and nitrogen. The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier.

In another aspect the invention provides a composition comprising a therapeutically effective amount of an phosphodiesterase inhibitor (PDE inhibitor), which can optionally be substituted with at least one NO or  $\text{NO}_2$  moiety, and one to ten fold molar excess of a compound that donates, transfers or releases nitrogen monoxide as a charged species, *i.e.*, nitrosonium ( $\text{NO}^+$ ) or nitroxyl ( $\text{NO}^-$ ), or as the neutral species, nitric oxide ( $\text{NO}^\bullet$ ). The invention also provides compositions comprising such compounds in a pharmaceutically acceptable carrier.

In another aspect, the invention provides a method for treating male impotence in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor.

In another aspect, the invention provides a method for treating male impotence in humans which comprises administering to an individual in need thereof a composition comprising a therapeutically effective amount of an PDE inhibitor which can optionally

be substituted with at least one NO or NO<sub>2</sub> moiety, and a compound that donates, transfers or releases nitric oxide as a charged species, *i.e.*, nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO•). The PDE inhibitor or PDE inhibitor directly or indirectly linked to at least one NO or NO<sub>2</sub> group, and nitric oxide donor can be administered separately or as components of the same composition.

In another aspect, the invention provides a method for treating female sexual dysfunction in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor.

In another aspect, the invention provides a method for treating treating female sexual dysfunction in humans which comprises administering to an individual in need thereof a composition comprising a therapeutically effective amount of an PDE inhibitor which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety, and a compound that donates, transfers or releases nitric oxide as a charged species, *i.e.*, nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO•). The PDE inhibitor or PDE inhibitor directly or indirectly linked to at least one NO or NO<sub>2</sub> group, and nitric oxide donor can be administered separately or as components of the same composition.

In another aspect, the invention provides a method for treating anal disease resulting from excessive anal sphincter tone in humans which comprises administering to an individual in need thereof a therapeutically effective amount of a nitrosated or nitrosylated PDE inhibitor.

In another aspect, the invention provides a method for treating treating anal disease resulting from excessive anal sphincter tone in humans which comprises administering to an individual in need thereof a composition comprising a therapeutically effective amount of an PDE inhibitor which can optionally be substituted with at least one NO or NO<sub>2</sub> moiety, and a compound that donates, transfers or releases nitric oxide as a charged species, *i.e.*, nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO•). The PDE inhibitor or PDE inhibitor directly or indirectly linked to at least one NO or NO<sub>2</sub> group, and nitric oxide donor can be administered separately or as components of the same composition.

The nitrosated or nitrosylated PDE inhibitor and the compound that donates, transfers or releases nitric oxide and/or stimulates endogenous production of NO or EDRF *in vivo* can be administered separately or as components of the same composition in one or more pharmaceutically acceptable carriers.

The following drawings are illustrative of embodiments of the invention and do not limit the scope of the invention as defined by the claims.

- Figure 1** Synthetic scheme for the preparation of nitrite containing substituted benzene derivatives.
- Figure 2** Synthetic scheme for the preparation of nitrosothiol containing substituted benzene derivatives.
- Figure 3** Synthetic scheme for the preparation of nitrate containing substituted benzene derivatives.
- Figure 4** Synthetic scheme for the preparation of nitrite containing imidazo[2,1-b]quinazoline derivatives.
- Figure 5** Synthetic scheme for the preparation of nitrosothiol containing imidazo[2,1-b]quinazoline derivatives.
- Figure 6** Synthetic scheme for the preparation of nitrate containing imidazo[2,1-b]quinazoline derivatives.
- Figure 7** Synthetic scheme for the preparation of nitrite containing purine-6-one derivatives.
- Figure 8** Synthetic scheme for the preparation of nitrosothiol containing purine-6-one derivatives.



- Figure 9** Synthetic scheme for the preparation of nitrate containing purine-6-one derivatives.
- Figure 10** Synthetic scheme for the preparation of nitrite containing pyrimidin-4-one derivatives.
- Figure 11** Synthetic scheme for the preparation of nitrosothiol containing pyrimidin-4-one derivatives.
- Figure 12** Synthetic scheme for the preparation of nitrate containing pyrimidin-4-one derivatives.
- Figure 13** Synthetic scheme for the preparation of nitrite containing 2-pyridone derivatives.
- Figure 14** Synthetic scheme for the preparation of nitrosothiol containing 2-pyridone derivatives.
- Figure 15** Synthetic scheme for the preparation of nitrate containing 2-pyridone derivatives.
- Figure 16** Synthetic scheme for the preparation of nitrite containing purine-2,6-dione derivatives.
- Figure 17** Synthetic scheme for the preparation of nitrosothiol containing purine-2,6-dione derivatives.
- Figure 18** Synthetic scheme for the preparation of nitrate containing purine-2,6-dione derivatives.
- Figure 19** Synthetic scheme for the preparation of nitrite containing quinoline derivatives.

- Figure 20** Synthetic scheme for the preparation of nitrosothiol containing quinoline derivatives.
- Figure 21** Synthetic scheme for the preparation of nitrate containing quinoline derivatives.
- Figure 22** Synthetic scheme for the preparation of nitrite containing substituted pyridine derivatives.
- Figure 23** Synthetic scheme for the preparation of nitrosothiol containing substituted pyridine derivatives.
- Figure 24** Synthetic scheme for the preparation of nitrate containing substituted pyridine derivatives.
- Figure 25** Synthetic scheme for the preparation of nitrite containing benzo[c] [1,6]naphthyridine derivatives.
- Figure 26** Synthetic scheme for the preparation of nitrosothiol containing benzo[c] [1,6]naphthyridine derivatives.
- Figure 27** Synthetic scheme for the preparation of nitrate containing benzo[c] [1,6]naphthyridine derivatives.
- Figure 28** Synthetic scheme for the preparation of nitrite containing 2,6-dihydroxyalkylamino-4,8-dipiperidino pyrimido [5,4-d]pyrimidine derivatives.
- Figure 29** Synthetic scheme for the preparation of nitrosothiol containing 2,6-dihydroxyalkylamino-4,8-dipiperidino pyrimido [5,4-d]pyrimidine derivatives.
- Figure 30** Synthetic scheme for the preparation of nitrate containing 2,6-dihydroxyalkylamino-4,8-dipiperidino pyrimido

[5,4-d]pyrimidine derivatives.

**Figure 31** Synthetic scheme for the preparation of nitrite containing 1-((3,4-dihydroxyphenyl)methyl)-6,7-isoquinoline derivatives.

**Figure 32** Synthetic scheme for the preparation of nitrosothiol containing 1-((3,4-dihydroxyphenyl)methyl)-6,7-isoquinoline derivatives.

**Figure 33** Synthetic scheme for the preparation of nitrate containing 1-((3,4-dihydroxyphenyl)methyl)-6,7-isoquinoline derivatives.

**Figure 34** Synthetic scheme for the preparation of nitrite containing substituted quinazoline derivatives.

**Figure 35** Synthetic scheme for the preparation of nitrosothiol containing substituted quinazoline derivatives.

**Figure 36** Synthetic scheme for the preparation of nitrate containing substituted quinazoline derivatives.

**Figure 37** Synthetic scheme for the preparation of nitrite containing substituted phenol derivatives.

**Figure 38** Synthetic scheme for the preparation of nitrosothiol containing substituted phenol derivatives.

**Figure 39** Synthetic scheme for the preparation of nitrate containing substituted phenol derivatives.

**Figure 40** Graph of comparative in vitro relaxation effects of dipyrindamole and Example 1 in phenylephrine

induced contacted human corpus cavernosum tissue.

The term "lower alkyl" as used herein refers to branched or straight chain alkyl groups comprising one to ten carbon atoms, including methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, neopentyl and the like.

The term "alkoxy" as used herein refers to  $R_{50}O$ -wherein  $R_{50}$  is lower alkyl as defined in this specification. Representative examples of alkoxy groups include methoxy, ethoxy, t-butoxy and the like.

The term "alkoxyalkyl" as used herein refers to an alkoxy group as previously defined appended to an alkyl group as previously defined. Examples of alkoxyalkyl include, but are not limited to, methoxymethyl, methoxyethyl, isopropoxymethyl and the like.

The term "hydroxy" as used herein refers to  $-OH$ .

The term "hydroxyalkyl" as used herein refers to a hydroxy group as previously defined appended to a lower alkyl group as previously defined.

The term "alkenyl" as used herein refers to a branched or straight chain  $C_2-C_{10}$  hydrocarbon which also comprises one or more carbon-carbon double bonds.

The term "amino" as used herein refers to  $-NH_2$ .

The term "nitrate" as used herein refers to  $-O-NO_2$ .

The term "alkylamino" as used herein refers to  $R_{50}NH$ -wherein  $R_{50}$  is as defined in this specification, for example, methylamino, ethylamino, butylamino, and the like.

The term "dialkylamino" as used herein refers to  $R_{52}R_{53}N$ -wherein  $R_{52}$  and  $R_{53}$  are independently selected from lower alkyl groups as defined in this specification, for example dimethylamino, diethylamino, methyl propylamino and the like.

The term "nitro" as used herein refers to the group  $-NO_2$  and "nitrosated" refers to compounds that have been substituted therewith.

The term "nitroso" as used herein refers to the group  $-NO$  and "nitrosylated" refers to compounds that have been substituted therewith.

The term "aryl" as used herein refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. Aryl groups (including bicyclic aryl groups) can be unsubstituted or substituted with one, two or three substituents independently selected from lower alkyl, haloalkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, and nitro. In addition, substituted aryl groups include tetrafluorophenyl and pentafluorophenyl.

The term "alkylaryl" as used herein refers to a lower alkyl radical to which is appended an aryl group. Representative arylalkyl groups include benzyl, phenylethyl, hydroxybenzyl, fluorobenzyl, fluorophenylethyl and the like.

The term "arylalkoxy" as used herein refers to an alkoxy radical to which is appended an aryl group. Representative arylalkoxy groups include benzyloxy, phenylethoxy, chlorophenylethoxy and the like.

The term "cycloalkyl" as used herein refers to an alicyclic group comprising from 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The term "bridged cycloalkyl" herein refers to two or more cycloalkyl radicals fused via adjacent or non-adjacent carbon atoms, including but not limited to adamantyl and decahydronaphthyl.

The term "cycloalkoxy" as used herein refers to  $R_{54}O-$  wherein  $R_{54}$  is cycloalkyl as defined in this specification. Representative examples of alkoxy groups include cyclopropoxy, cyclopentyloxy, and cyclohexyloxy and the like.

The term "arylthio" herein refers to  $R_{55}S$ - wherein  $R_{55}$  is an aryl group.

The term "alkylsulfinyl" herein refers to  $R_{50}-S(O)_2$ - wherein  $R_{50}$  is as defined in this specification.

The term "carboxamido" herein refers to  $-C(O)NH_2$ .

The term "carbamoyl" herein refers to  $-O-C(O)NH_2$ .

The term "carboxyl" herein refers to  $-CO_2H$ .

The term "carbonyl" herein refers to  $-C(O)-$ .

The term "halogen" or "halo" as used herein refers to I, Br, Cl, or F.

The term "haloalkyl" as used herein refers to a lower alkyl radical to which is appended one or more halogens. Representative examples of a haloalkyl group include trifluoromethyl, chloromethyl, 2-bromobutyl, 1-bromo-2-chloro-pentyl and the like.

The term "haloalkoxy" as used herein refers to a haloalkyl radical to which is appended an alkoxy group. Representative examples of haloalkoxy groups include, 1,1,1-trichloroethoxy, 2-bromobutoxy and the like.

The term "heteroaryl" as used herein refers to a mono- or bi- cyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring. Heteroaryl groups (including bicyclic heteroaryl groups) can be unsubstituted or substituted with one, two or three substituents independently selected from lower alkyl, haloalkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, halo and nitro. Examples of heteroaryl groups include but are not limited to pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, thiazole, isothiazole, benzothiazole, benzoxazole, thiadiazole, oxazole, pyrrole, imidazole and isoxazole.

The term "heterocyclic ring" refers to any 3-, 4-, 5-, 6-, or 7-membered nonaromatic ring containing at least one nitrogen atom, oxygen, or sulfur atom which is bonded to an atom which is not part of the heterocyclic ring.

The term "arylheterocyclic ring" as used herein refers to a bi- or tricyclic ring comprised of an aryl ring as previously defined appended via two adjacent carbons of the aryl group to a heterocyclic ring as previously defined.

The term "heterocyclic compounds" herein refers to mono and polycyclic compounds containing at least one heteroaryl or heterocyclic ring.

The term "amido" as used herein refers to  $\text{-NH-C(O)-R}_{56}$  wherein  $\text{R}_{56}$  is a lower alkyl, aryl, or heteroaryl group as defined in this specification


The term "alkylamido" as used herein refers to  $\text{R}_{50}\text{N-C(O)-R}_{56}$  wherein  $\text{R}_{50}$  is as defined in this specification and  $\text{R}_{56}$  is a lower alkyl, aryl, or heteroaryl group as defined in this specification.

Examples of contemplated PDE inhibitors to which a nitric oxide adduct may be directly or indirectly linked include dipyridamole, zaprinast, sildenafil, flaminast, denbufyllene, piclamilast, zardaverine, rolipram, papaveroline, E4021, and triflusal.

Sources of information for the above include Goodman and Gilman, The Pharmacological Basis of Therapeutics (9th Ed.), McGraw-Hill, Inc., 1996; the Physician's Desk Reference (49th Ed.), Medical Economics (1995); Drug Facts and Comparisons (1993 Ed), Facts and Comparisons (1993); and The Merck Index (12th Ed.), Merck & Co., Inc. (1996), all of which are incorporated herein by reference in their entirety.

A principal aspect of the invention relates to novel nitrosated and/or nitrosylated phosphodiesterase inhibitors.


One embodiment of this aspect provides compounds having the structure:



I

wherein,

R<sub>1</sub> is alkoxy, cycloalkoxy, halogen, or




R<sub>2</sub> is hydrogen, alkoxy, or haloalkoxy; and


R<sub>3</sub> is selected from:




(i)




(ii)




(iii)




(iv)




(v)




(vi)




(vii)




(viii)



(ix)



(x)



wherein

D is selected from (i) -NO; (ii) -NO<sub>2</sub>; (iii) -C(R<sub>d</sub>)-O-C(O)-Y-Z-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T-Q in which R<sub>d</sub> is hydrogen, lower alkyl, cycloalkyl, aryl, alkylaryl, aryl or heteroaryl, Y is oxygen, sulfur, or NR<sub>i</sub> in which R<sub>i</sub> is hydrogen, lower alkyl, R<sub>e</sub> and R<sub>f</sub> at each occurrence are independently selected from hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, amino, alkylamino, amido, alkylamido, dialkylamino, carboxy, or taken together are carbonyl, cycloalkyl or bridged cycloalkyl, p is an integer from 1 to 6, T is a covalent bond, oxygen, sulfur or nitrogen, Z is selected from a covalent bond, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or arylheterocyclic ring, and Q is selected from -NO or -NO<sub>2</sub>; (iv) -C(O)-T<sup>1</sup>-Z-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T<sup>2</sup>-Q wherein T<sup>1</sup> and T<sup>2</sup> are independently selected from T and R<sub>e</sub>, R<sub>f</sub>, p, Q, Z, and T are as defined in this specification; (v) -C(O)-Z-[G-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T-Q]<sub>p</sub> wherein G is (i) a covalent bond; (ii) -T-C(O)-; (iii) -C(O)-T, or (iv) Y, and wherein R<sub>e</sub>, R<sub>f</sub>, p, Q, T, Y, and Z are as defined in this specification; (v) -C(O)-T[C(R<sub>y</sub>)(R<sub>z</sub>)]<sub>p</sub> wherein R<sub>y</sub> and R<sub>z</sub> are independently selected from -T<sup>1</sup>-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-G-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T<sup>2</sup>-Q wherein G, R<sub>e</sub>, R<sub>f</sub>, p, Q, T, T<sup>1</sup>, and T<sup>2</sup> are as defined in this specification;

R<sub>4</sub> is selected from (i) hydrogen, (ii) -C(R<sub>d</sub>)-O-C(O)-Y-Z-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T-Q, (iii) -C(O)-T<sup>1</sup>-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T<sup>2</sup>-Q, (iv) -C(O)-Z-[G-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T-Q]<sub>p</sub>; and wherein R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>, p, G, T, T<sup>1</sup>, T<sup>2</sup>, Q, Y, and Z are defined as in this specification;


R<sub>5</sub> is selected from a lone pair of electrons or -C(R<sub>d</sub>)-O-C(O)-Y-Z-[C(R<sub>e</sub>)(R<sub>f</sub>)]<sub>p</sub>-T-Q wherein R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>, p, T, T<sup>1</sup>, T<sup>2</sup>, Q, Y, and Z are defined as in this specification;

R<sub>11</sub> and R<sub>12</sub> are independently selected from hydrogen or R<sub>4</sub> wherein R<sub>4</sub> is as defined in this specification with the provision that R<sub>11</sub> and R<sub>12</sub> are not both hydrogen;

X is a halogen and;

D<sub>1</sub> is selected from D or hydrogen and wherein D is as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:



II

wherein,


$R_4$  is as defined in this specification;

$R_8$  is selected from hydrogen or lower alkyl;


$R_9$  is selected from hydrogen or halogen; and

$R_{10}$  is selected from:

(i) hydrogen




(iii)



wherein  $R_8$  is as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:



III


wherein,

E is selected from nitrogen or -CH-;


G is selected from nitrogen or -C(R<sub>8</sub>)-;

R<sub>21</sub> is selected from:

(i)




(ii)



R<sub>22</sub> is selected from R<sub>12</sub> or lower alkyl; and

R<sub>8</sub>, R<sub>11</sub>, and R<sub>12</sub> are as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:



IV








wherein,

F is selected from -CH<sub>2</sub>- or sulfur;

R<sub>4</sub> and R<sub>8</sub> are as defined in this specification; and

R<sub>13</sub> is selected from:


1000000-1000000



wherein,

$R_6$  and  $R_7$  are independently selected from hydrogen or  $R_4$  wherein  $R_4$  is as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:




V


wherein,

 $R_4$  is as defined in this specification; and $R_{14}$  is selected from:


(i)




(ii)



(iii)




(iv)



wherein  $R_6$  is as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:



VI


wherein,

$R_{15}$  is hydrogen, lower alkyl,  $R_4$ , or  $-(CH_2)_4-C(CH_3)_2-O-D_1$ ;

$R_{16}$  is lower alkyl; and

$R_{17}$  is hydrogen, lower alkyl,  $CH_3-C(O)-CH_2-$ ,  $CH_3-O-CH_2-$ , or D with the provision that either  $R_{15}$  or  $R_{17}$  must be selected to contain D and wherein D and  $D_1$  are as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:



VII


wherein,

$R_4$  and  $R_8$  are as defined in this specification and


$R_{18}$  is selected from:



(i)




(ii)



and wherein  $R_8$  is as defined in this specification.

Another embodiment of this aspect provides compounds having the structure:




VIII


wherein,

$R_{19}$  is selected from:


(i)




(ii)



(iii)




(iv)



and wherein  $R_4$ ,  $R_{11}$ , and  $R_{12}$  are defined as in this specification.

Another embodiment of this aspect provides compounds having the structure:



IX


wherein,

$R_{20}$  is selected from:

(i)




(ii)



and wherein  $R_4$  is defined as in this specification.

Another embodiment of this aspect provides compounds having the structure:




X

wherein,

$a$  is an integer from 2 to 3 and  $D$  and  $D_1$  are defined as in this specification.


Another embodiment of this aspect provides compounds having the structure:



XI

wherein D and D<sub>1</sub> are defined as in this specification.



Another embodiment of this aspect provides compounds having the structure:





XII

wherein,

J is selected from:




K is selected from:



wherein V is carbon or nitrogen;

$R_{25}$ ,  $R_{24}$ ,  $R_{25}$ ,  $R_{26}$ ,  $R_{27}$ ,  $R_{28}$ ,  $R_{29}$ , and  $R_{30}$  are independently selected from hydrogen, halogen, alkoxy, nitrile, carboxamido, or carboxyl; and wherein  $p$ ,  $R_6$ ,  $R_7$ ,  $T$ ,  $T^1$ ,  $T^2$ ,  $Y$  and  $D$  are defined as in this specification.

Another embodiment of this aspect provides compounds having the structure:



XIII

wherein,

$R_{31}$  is alkyl, halogen, haloalkyl, or haloalkoxy;

$R_{32}$  is selected from  $D_1$  or  $-C(O)-R_8$ ; and

1

Another aspect of the invention provides processes for making the novel compounds of the invention and to the intermediates useful in such processes.

[illegible]

-30-

Nitroso compounds of formula (I) wherein  $R_1$ ,  $R_2$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrite containing imide is representative of the  $R_3$  group as defined in this specification may be prepared as outlined in Figure 1. The amide group of formula 1 is converted to the imide of formula 2 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected alcohol containing acid in the presence of pyridine at low temperature or condensing the amide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl ether, a tert-butyl dimethylsilyl ether, or a tert-butyl diphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula 1A.

Nitroso compounds of formula (I) wherein  $R_1$ ,  $R_2$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrosothiol containing imide is representative of the  $R_3$  group as defined in this specification may be prepared as outlined in Figure 2. The amide group of formula 1 is converted to the imide of formula 3 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected thiol containing acid in the presence of pyridine at low temperature or condensing the amide and protected thiol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing

disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **IB**. Alternatively, treatment of the deprotected thiol derived from compound **3** with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula **IB**.

Nitro compounds of formula (I) wherein  $R_1$ ,  $R_2$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and an nitrate containing imide is representative of the  $R_3$  group as defined in this specification may be prepared as outlined in Figure 3. The amide group of the formula **1** is converted to the imide of the formula **4** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the halide containing acid in the presence of pyridine at low temperature or condensing the amide and halide containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred halides are bromide and iodide. Reaction of the imide of the formula **4** with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula **IC**.

Another embodiment of this aspect provides processes for making compounds having structures **II** and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (II) wherein  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification, and a nitrite containing amide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 4. The imidazo[2,1-b]quinazoline of formula **5** is converted to the acylimidazo[2,1-b]quinazoline of formula **6** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an



appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of acylimidazo[2,1-b]quinazolines are reacting the imidazo[2,1-b]quinazoline with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid or condensing the imidazo[2,1-b]quinazoline and protected alcohol containing acid in the presence of a dehydrating agent such as dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC · HCl) with or without a catalyst such as 4-dimethylaminopyridine (DMAP) or 1-hydroxybenzotriazole (HOBT). Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **IIA**.

Nitroso compounds of formula **(II)** wherein  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification, and a nitrosothiol containing amide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 5. The imidazo[2,1-b]quinazoline of formula **5** is converted to the acylimidazo[2,1-b]quinazoline of formula **7** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of acylated imidazo[2,1-b]quinazolines are reacting the imidazo[2,1-b]quinazoline with the preformed acid chloride or symmetrical anhydride of the protected thiol containing acid or condensing the imidazo[2,1-b]quinazoline and protected thiol containing acid in the presence of a dehydrating agent such as DCC or EDAC · HCl with or without a catalyst such as DMAP or HOBT. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl

thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IIB. Alternatively, treatment of the deprotected thiol derived from compound 7 with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula IIB.

Nitro compounds of formula (II) wherein  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_c$ ,  $R_f$ , and  $p$  are defined as in this specification, and a nitrate containing amide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 6. The imidazo[2,1-b]quinazoline of formula 5 is converted to the acylimidazo[2,1-b]quinazoline of formula 8 wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of the acylimidazo[2,1-b]quinazolines are reacting the imidazo[2,1-b]quinazoline with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the alcohol and halide containing acid in the presence of a dehydrating agent such as DCC or EDAC·HCl with or without a catalyst such as DMAP or HOBt. Preferred halides are bromide and iodide. Reaction of the acylimidazo[2,1-b]quinazoline of the formula 8 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula IIC.

Another embodiment of this aspect provides processes for making compounds having structures III and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (III) wherein  $E$ ,  $G$ ,  $R_{21}$ ,  $R_{22}$ ,  $R_c$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrite containing amide is representative of the  $R_{11}$  group as defined in this specification may be prepared as outlined in Figure 7. The purine-6-one group of formula 9 is converted to the acylated purine-6-one of formula 10 wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification by reaction with an appropriate

protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of acylated purine-6-ones are reacting the purine-6-one with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IIIA.

Nitroso compounds of formula (III) wherein E, G,  $R_{21}$ ,  $R_{22}$ ,  $R_e$ ,  $R_f$ , and p are defined as in this specification and an nitrosothiol containing amide is representative of the  $R_{11}$  group as defined in this specification may be prepared as outlined in Figure 8. The purine-6-one group of formula 9 is converted to the acylated purine-6-one of formula 11 wherein p,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of acylated purine-6-ones are reacting the purine-6-one with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine

affords the compound of the formula **IIIB**. Alternatively, treatment of the deprotected thiol derived from compound **11** with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula **IIIB**.

Nitro compounds of formula (**III**) wherein E, G, R<sub>21</sub>, R<sub>22</sub>, R<sub>e</sub>, R<sub>f</sub>, and p are defined as in this specification and an nitrate containing amide is representative of the R<sub>11</sub> group as defined in this specification may be prepared as outlined in Figure 9. The purine-6-one of formula 9 is converted to the acylated purine-6-one of the formula 12 wherein p, R<sub>e</sub> and R<sub>f</sub> are defined and X is halogen. Preferred methods for the formation of acylated purine-6-ones are reacting the purine-6-one with the preformed acid chloride or symmetrical anhydride of the halide containing acid. Preferred halides are bromide and iodide. Reaction of the acylated purine-6-one of the formula 12 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula **IIIC**.

Another embodiment of this aspect provides processes for making compounds having structures **IV** and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (**IV**) wherein F, R<sub>8</sub>, R<sub>13</sub>, R<sub>c</sub>, R<sub>f</sub>, and p are defined as in this specification and a nitrite containing acyl hydrazide is representative of the R<sub>4</sub> group as defined in this specification may be prepared as outlined in Figure 10. The 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine of formula 13 is converted to the 3 (2-acyl)-pyridazinone or 2-acyl-1, 2, 3, 4-thiadiazine of formula 14 wherein p, R<sub>c</sub> and R<sub>f</sub> are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein P<sup>1</sup> is as defined in this specification. Preferred methods for the formation of 3 (2-acyl)-pyridazinone or 2-acyl-1, 2, 3, 4-thiadiazine are reacting the 3 (2H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid or condensing the 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine and protected alcohol containing acid in the presence of a dehydrating agent such as DCC or EDAC. HCl with a catalyst such as DMAP or HOBt. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating

agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IVA.

Nitroso compounds of formula (IV) wherein F, R<sub>8</sub>, R<sub>13</sub>, R<sub>9</sub>, R<sub>6</sub>, and p are defined as in this specification and a nitrosothiol containing acyl hydrazide is representative of the R<sub>4</sub> group as defined in this specification may be prepared as outlined in Figure 11. The 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine of formula 13 is converted to the 3 (2-acyl)-pyridazinone or 2-acyl-1, 2, 3, 4-thiadiazine of formula 15 wherein p, R<sub>4</sub>, and R<sub>6</sub> are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein P<sup>2</sup> is as defined in this specification. Preferred methods for the formation of 3 (2-acyl)-pyridazinones or 2-acyl-1, 2, 3, 4-thiadiazines are reacting the 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine with the preformed acid chloride or symmetrical anhydride of the protected thiol containing acid or condensing the 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine and protected thiol containing acid in the presence of a dehydrating agent such as DCC or EDAC . HCl with a catalyst such as DMAP or HOBt. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IVB. Alternatively, treatment of the deprotected thiol derived from compound 15 with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula IVB.

Nitro compounds of formula (IV) wherein F, R<sub>8</sub>, R<sub>13</sub>, R<sub>e</sub>, R<sub>f</sub>, and p are defined as in this specification and an nitrate-containing acyl hydrazide is representative of the R<sub>4</sub> group as defined in this specification may be prepared as outlined in Figure 12. The 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine of formula 13 is converted to the 3 (2-acyl)-pyridazinone or 2-acyl-1, 2, 3, 4-thiadiazine of formula 16 wherein p, R<sub>e</sub> and R<sub>f</sub> are defined and X is halogen. Preferred methods for the formation of 3 (2-acyl)-pyridazinones or 2-acyl-1, 2, 3, 4-thiadiazines are reacting the 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the 3 (2-H)-pyridazinone or 2H-1, 2, 3, 4-thiadiazine and halide containing acid in the presence of a dehydrating agent such as DCC or EDAC . HCl with a catalyst such as DMAP or HOBT. Preferred halides are bromide and iodide. Reaction of the 3 (2-acyl)-pyridazinone or 2-acyl-1, 2, 3, 4-thiadiazine of formula 16 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula IVc.

Another embodiment of this aspect provides processes for making compounds having structures V and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (V) wherein R<sub>14</sub>, R<sub>e</sub>, R<sub>f</sub>, and p are defined as in this specification and an nitrite containing imide is representative of the R<sub>4</sub> group as defined in this specification may be prepared as outlined in Figure 13. The amide group of formula 17 is converted to the imide of formula 18 wherein p, R<sub>e</sub> and R<sub>f</sub> are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein P<sup>1</sup> is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected alcohol containing acid in the presence of pyridine at low temperature or condensing the amide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane,

THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VA.

Nitroso compounds of formula (V) wherein  $R_{14}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrosothiol containing imide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 14. The amide group of formula 17 is converted to the imide of formula 19 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected thiol containing acid in the presence of pyridine at low temperature or condensing the amide and protected thiol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VB. Alternatively, treatment of the deprotected thiol derived from compound 19 with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula VB.

Nitro compounds of formula (V) wherein  $R_{14}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrate containing imide is representative of the  $R_4$  group as defined

in this specification may be prepared as outlined in Figure 15. The amide group of the formula 17 is converted to the imide of the formula 20 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the halide containing acid in the presence of pyridine at low temperature or condensing the amide and halide containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred halides are bromide and iodide. Reaction of the imide of the formula 20 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula VC.

Another embodiment of this aspect provides processes for making compounds having structures VI and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (VI) wherein  $R_{15}$ ,  $R_{16}$ ,  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and a nitrite containing acyl imidazolide is representative of the  $R_{17}$  group as defined in this specification may be prepared as outlined in Figure 16. The 1H-purine-2, 6-dione of formula 21 is converted to the acylated derivative of the formula 22 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of acylated 1H-purine-2, 6-diones are reacting the 1H-purine-2, 6-dione with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid or condensing the 1H-purine-2, 6-dione and protected alcohol containing acid in the presence of a dehydrating agent such as DCC or EDAC . HCl with a catalyst such as DMAP or HOBT. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VIA.



Nitroso compounds of formula (VI) wherein  $R_{15}$ ,  $R_{16}$ ,  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and a nitrosothiol containing acyl imidazolidine is representative of the  $R_{17}$  group as defined in this specification may be prepared as outlined in Figure 17. The 1H-purine-2, 6-dione of formula 21 is converted to the acylated derivative of the formula 23 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of acylated 1H-purine-2, 6-diones are reacting the 1H-purine-2, 6-dione with the preformed acid chloride or symmetrical anhydride of the protected thiol containing acid or condensing the 1H-purine-2, 6-dione and protected thiol containing acid in the presence of a dehydrating agent such as DCC or EDAC . HCl with a catalyst such as DMAP or HOBt. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VIB. Alternatively, treatment of the deprotected thiol derived from compound 23 with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula VIB.

Nitro compounds of formula (VI) wherein  $R_{15}$ ,  $R_{16}$ ,  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and an O-nitrosated acylated 1H-purine-2, 6-dione is representative of the  $R_{17}$  group as defined in this specification may be prepared as outlined in Figure 18. The 1H-purine-2, 6-dione of the formula 21 is converted to the acylated derivative of the formula 24 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen

by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of acylated 1H-purine-2, 6-diones are reacting the 1H-purine-2, 6-dione with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the 1H-purine-2, 6-dione and halide containing acid in the presence of a dehydrating agent such as DCC or EDAC . HCl with a catalyst such as DMAP or HOBt. Preferred halides are bromide and iodide. Reaction of the acylated 1H-purine-2, 6-dione of the formula 24 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula VIC.

Another embodiment of this aspect provides processes for making compounds having structures VII and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (VII) wherein  $R_8$ ,  $R_{18}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrite containing imide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 19. The amide nitrogen of formula 25 is converted to the imide of formula 26 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected alcohol containing acid in the presence of pyridine at low temperature or condensing the amide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VIIA.

Nitroso compounds of formula (VII) wherein  $R_8$ ,  $R_{18}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrosothiol containing imide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 20. The amide nitrogen of formula 25 is converted to the imide of formula 27 wherein  $p$ ,  $R_e$  and  $R_f$  are

defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected thiol containing acid in the presence of pyridine at low temperature or condensing the amide and protected thiol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **VIIb**. Alternatively, treatment of the deprotected thiol derived from compound **27** with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula **VIIb**.

Nitro compounds of formula (**VII**) wherein  $R_8$ ,  $R_{18}$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrate containing imide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 21. The amide group of the formula **25** is converted to the imide of the formula **28** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the halide containing acid in the presence of pyridine at low temperature or condensing the amide and halide containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred halides are bromide and iodide. Reaction of the imide of the formula **28** with a suitable

nitration agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula VIIC.

Another embodiment of this aspect provides processes for making compounds having structures VIII and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (VIII) wherein  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and a nitrite containing imide is representative of the  $R_{19}$  group as defined in this specification may be prepared as outlined in Figure 22. The amide nitrogen of formula 29 is converted to the imide of formula 30 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected alcohol containing acid in the presence of pyridine at low temperature or condensing the amide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula VIIIA.

Nitroso compounds of formula (VIII) wherein  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and a nitrosothiol containing imide is representative of the  $R_{19}$  group as defined in this specification may be prepared as outlined in Figure 23. The amide nitrogen of formula 29 is converted to the imide of formula 31 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the protected thiol containing acid in the presence of pyridine at low temperature or condensing the amide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups

for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **VIIIB**. Alternatively, treatment of the deprotected thiol derived from compound **31** with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula **VIIIB**.

Nitro compounds of formula (**VIII**) wherein  $R_e$ ,  $R_f$  and  $p$  are defined as in this specification and a nitrate containing imide is representative of the  $R_{19}$  group as defined in this specification may be prepared as outlined in Figure 24. The amide group of the formula **29** is converted to the imide of the formula **32** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of imides are reacting the amide with the preformed acid chloride of the halide containing acid in the presence of pyridine at low temperature or condensing the amide and halide containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred halides are bromide and iodide. Reaction of the imide of the formula **32** with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula **VIIIC**.

Another embodiment of this aspect provides processes for making compounds having structures **IX** and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (IX) wherein  $R_{20}$ ,  $R_c$ ,  $R_f$  and  $p$  are defined as in this specification and an nitrate containing imide or sulfonimide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 25. The amide or sulfonamide nitrogen of formula 33 is converted to the imide or sulfonimide of formula 34 wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of imides or sulfonimides are reacting the amide or sulfonimide with the preformed acid chloride of the protected alcohol containing acid in the presence of pyridine at low temperature or condensing the amide or sulfonimide and protected alcohol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the alcohol moiety are silyl ethers such as a tert-butyldimethylsilyl ether or a tert-butyldiphenylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IXA.

Nitroso compounds of formula (IX) wherein  $R_{20}$ ,  $R_c$ ,  $R_f$  and  $p$  are defined as in this specification and an nitrosothiol containing imide or sulfonimide is representative of the  $R_4$  group as defined in this specification may be prepared as outlined in Figure 26. The amide or sulfonamide nitrogen of formula 33 is converted to the imide or sulfonimide of formula 35 wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of imides or sulfonimides are reacting the amide or sulfonimide with the preformed acid chloride of the protected thiol containing acid in the presence of pyridine at low temperature or condensing the amide or sulfonimide and protected thiol containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranlyl thioether or a 2,4,6-trimethoxybenzyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid,

triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether, or a 2,4,6-trimethoxybenzyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula IXB. Alternatively, treatment of the deprotected thiol derived from compound 35 with a stoichiometric quantity of sodium nitrite in an acidic aqueous or alcoholic solution affords the compound of the formula IXB.

Nitro compounds of formula (IX) wherein  $R_{20}$ ,  $R_c$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrate containing imide or sulfonimide is representative of the  $R_d$  group as defined in this specification may be prepared as outlined in Figure 27. The amide or sulfonamide group of the formula 33 is converted to the imide or sulfonimide of the formula 36 wherein  $p$ ,  $R_c$ , and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of imides or sulfonimides are reacting the amide or sulfonamide with the preformed acid chloride of the halide containing acid in the presence of pyridine at low temperature or condensing the amide or sulfonamide and halide containing symmetrical anhydride in the presence of a catalyst such as sulfuric acid. Preferred halides are bromide and iodide. Reaction of the imide or sulfonimide of the formula 36 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula IXC.

Another embodiment of this aspect provides processes for making compounds having structures X and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (X) wherein  $D_1$ ,  $R_c$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrite containing ester is representative of the  $D$  group as defined in this specification may be prepared according to Scheme 28. The alcohol group of

formula 37 is converted to the ester of formula 38 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid or condensing the alcohol and protected alcohol containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or a tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula XA.

Nitroso compounds of formula (X) wherein  $D_1$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrosothiol containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 29. The alcohol group of the formula 37 is converted to the ester of the formula 39 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the protected thiol containing acid or condensing the alcohol and protected thiol containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred protecting groups for the thiol moiety are as a thioester such as a thioacetate or thiobenzoate, as a disulfide, as a thiocarbamate such as N-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a S-triphenylmethyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and N-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a



tetrahydropyranyl thioether or a S-triphenylmethyl thioether group) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **XB**. Alternatively, treatment of the deprotected thiol derived from compound **39** with a stoichiometric quantity of sodium nitrite in aqueous or alcoholic acid affords the compound of the formula **XB**.

Nitro compounds of formula (X) wherein  $D_1$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrate containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 30. The alcohol group of the formula **37** is converted to the ester of the formula **40** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and X is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the alcohol and halide containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred halides are bromide and iodide. Reaction of the ester of the formula **40** with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula **XC**.

Nitroso compounds of formula (XI) wherein  $D_1$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrite containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 31. The alcohol group of formula **41** is converted to the ester of formula **42** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing activated acylating agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the protected alcohol containing acid or condensing the alcohol and protected alcohol containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or a tert-butyl dimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the

preferred method for removing silyl ether protecting groups) followed by reaction a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **XIA**.

Nitroso compounds of formula **(XI)** wherein  $D_1$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrosothiol containing ester is representative of the  $D$  group as defined in this specification may be prepared according to Scheme 32. The alcohol group of the formula **41** is converted to the ester of the formula **43** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing activated acylating agent wherein  $P^2$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the protected thiol containing acid or condensing the alcohol and protected thiol containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred protecting groups for the thiol moiety are as a disulfide, a thioester such as a thioacetate or thiobenzoate, as a thiocarbamate such as *N*-methoxymethyl thiocarbamate, or as a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a *S*-triphenylmethyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while aqueous base is typically utilized to hydrolyze thioesters and *N*-methoxymethyl thiocarbamates and mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a *S*-triphenylmethyl thioether group) followed by reaction with a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as *tert*-butyl nitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **XIB**. Alternatively, treatment of the deprotected thiol derived from compound **43** with a stoichiometric quantity of sodium nitrite in aqueous or alcoholic acid affords the compound of the formula **XIB**.

Nitro compounds of formula (XI) wherein  $D_1$ ,  $R_e$ ,  $R_f$ , and  $p$  are defined as in this specification and a nitrate containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 33. The alcohol group of the formula 41 is converted to the ester of the formula 44 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing activated acylating agent. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the alcohol and halide containing acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred halides are bromide and iodide. Reaction of the ester of the formula 44 with a suitable nitrating agent such as silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula XIC.

Another embodiment of this aspect provides processes for making compounds having structures XII and to the intermediates useful in such processes as follows.

Nitroso compounds of formula (XII) wherein  $R_e$ ,  $R_f$ ,  $R_{23}$ ,  $R_{24}$ ,  $R_{25}$ ,  $J$ ,  $V$  and  $p$  are defined as in this specification and a nitrite containing thioester is representative of the K-T-D group as defined in this specification may be prepared according to Scheme 34. The carboxylic acid group of formula 45 is converted to the thioester of formula 46 wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing thiol agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of thioesters are reacting the thiol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the thiol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or a tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction with a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula XIIA.

Nitroso compounds of formula (XII) wherein  $R_e$ ,  $R_f$ ,  $R_{23}$ ,  $R_{24}$ ,  $R_{25}$ , J, V and p are defined as in this specification and a nitrosothiol containing thioester is representative of the K-T-D group as defined in this specification may be prepared according to Scheme 35. The carboxylic acid group of formula 45 is converted to the thioester of formula 47 wherein p,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate mono protected dithiol. Preferred methods for the formation of thioesters are reacting the free thiol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the free thiol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred protecting groups for the thiol moiety are as a disulfide, a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a S-triphenylmethyl thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a S-triphenylmethyl thioether group). Reaction of the free thiol with a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as tert-butyl nitrite, or nitrosium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula XIIB. Alternatively, treatment of the thiol in compound 47 with a stoichiometric quantity of sodium nitrite in aqueous or alcoholic acid affords the compound of the formula XIIB.

Nitro compounds of formula (XII) wherein  $R_e$ ,  $R_f$ ,  $R_{23}$ ,  $R_{24}$ ,  $R_{25}$ , J, V and p are defined as in this specification and a nitrate containing thioester is representative of the K-T-D group as defined in this specification may be prepared according to Scheme 36. The carboxylic acid group of formula 45 is converted to the thioester of formula 46 wherein p,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected alcohol containing thiol agent wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of thioesters are reacting the thiol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the thiol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred protecting groups for the

alcohol moiety are silyl ethers such as a trimethylsilyl or a tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction of the alcohol with a suitable nitrating agent such as nitric acid and acetic anhydride in ethyl acetate/acetic acid affords the compound of the formula **XIIC**.

Nitroso compounds of formula (**XIII**) wherein  $R_e$ ,  $R_f$ ,  $R_{31}$ ,  $R_{32}$ , and  $p$  are defined as in this specification and a nitrite containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 37. The carboxylic acid group of formula **48** is converted to the ester of formula **49** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an monoprotected protected diol wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the alcohol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or a tert-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction with a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, or nitrosonium tetrafluoroborate in a suitable anhydrous solvent such as dichloromethane, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **XIIIA**.

Nitroso compounds of formula (**XIII**) wherein  $R_e$ ,  $R_f$ ,  $R_{31}$ ,  $R_{32}$ , and  $p$  are defined as in this specification and a nitrosothiol containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 38. The carboxylic acid group of formula **48** is converted to the ester of formula **50** wherein  $p$ ,  $R_e$  and  $R_f$  are defined as in this specification by reaction with an appropriate protected thiol containing alcohol. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the primary thiol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBT. Preferred protecting groups for the thiol moiety are a disulfide, a thioether such as a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a S-triphenylmethyl

thioether. Deprotection of the thiol moiety (zinc in dilute aqueous acid, triphenylphosphine in water and sodium borohydride are preferred methods for reducing disulfide groups while mercuric trifluoroacetate, silver nitrate, or strong acids such as trifluoroacetic or hydrochloric acid and heat are used to remove a paramethoxybenzyl thioether, a tetrahydropyranyl thioether or a S-triphenylmethyl thioether group). Reaction of the free thiol with a suitable nitrosylating agent such as thionyl chloride nitrite, thionyl dinitrite, a lower alkyl nitrite such as *tert*-butyl nitrite, or nitrosium tetrafluoroborate in a suitable anhydrous solvent such as methylene chloride, THF, DMF, or acetonitrile with or without an amine base such as pyridine or triethylamine affords the compound of the formula **XIIIB**. Alternatively, treatment of the thiol in compound **50** with a stoichiometric quantity of sodium nitrite in aqueous or alcoholic acid affords the compound of the formula **XIIIB**.

Nitro compounds of formula (**XIII**) wherein  $R_c$ ,  $R_f$ ,  $R_{31}$ ,  $R_{32}$ , and  $p$  are defined as in this specification and a nitrate containing ester is representative of the D group as defined in this specification may be prepared according to Scheme 39. The carboxylic acid group of formula **48** is converted to the ester of formula **49** wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification by reaction with an appropriate monoprotected protected diol wherein  $P^1$  is as defined in this specification. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the carboxylic acid or condensing the alcohol and carboxylic acid with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred protecting groups for the alcohol moiety are silyl ethers such as a trimethylsilyl or a *tert*-butyldimethylsilyl ether. Deprotection of the hydroxyl moiety (fluoride ion is the preferred method for removing silyl ether protecting groups) followed by reaction of the alcohol with a suitable nitrating agent such as nitric acid and acetic anhydride in ethyl acetate/acetic acid affords the compound of the formula **XIIIC**. Alternatively, carboxylic acid group of the formula **48** is converted to the ester of the formula **51** wherein  $p$ ,  $R_c$  and  $R_f$  are defined as in this specification and  $X$  is a halogen by reaction with an appropriate halide containing alcohol. Preferred methods for the formation of esters are reacting the alcohol with the preformed acid chloride or symmetrical anhydride of the halide containing acid or condensing the alcohol and halide containing alcohol with a dehydrating agent such as DCC or EDAC. HCl in the presence of a catalyst such as DMAP or HOBt. Preferred halides are bromide and iodide. Reaction of the ester of the formula **51** with a suitable nitrating agent such as

silver nitrate in an inert solvent such as acetonitrile affords the compound of the formula XIIIIC.

As noted above, another aspect the invention provides a composition comprising (i) a therapeutically effective amount of a PDE inhibitor, which optionally can be substituted with at least one NO or NO<sub>2</sub> group or a group that stimulates endogenous production of NO or EDRF *in vivo*, and (ii) a compound that donates, transfers or releases nitrogen monoxide as a charged species, *i.e.*, nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO) and/or a compound that stimulates endogenous production of NO or EDRF *in vivo*.

The compounds that donate, transfer or release nitric oxide can be any of those known to the art, including those mentioned and/or exemplified below.

Nitrogen monoxide can exist in three forms: NO<sup>-</sup> (nitroxyl), NO<sup>-</sup> (nitric oxide) and NO<sup>+</sup> (nitrosonium). NO<sup>-</sup> is a highly reactive short-lived species that is potentially toxic to cells. This is critical, because the pharmacological efficacy of NO depends upon the form in which it is delivered. In contrast to NO<sup>-</sup>, nitrosonium and nitroxyl do not react with O<sub>2</sub> or O<sub>2</sub><sup>-</sup> species. Consequently, administration of NO equivalents does not result in the generation of toxic by-products or the elimination of the active NO moiety.

Compounds contemplated for use in the invention are nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer nitric oxide to a site of its activity, such as on a cell membrane, *in vivo*. As used here, the term "nitric oxide" encompasses uncharged nitric oxide (NO) and charged nitric oxide species, particularly including nitrosonium ion (NO<sup>+</sup>) and nitroxyl ion (NO<sup>-</sup>). The reactive form of nitric oxide can be provided by gaseous nitric oxide. The nitric oxide releasing, delivering or transferring compounds, having the structure F-NO wherein F is a nitric oxide releasing, delivering or transferring moiety, include any and all such compounds which provide nitric oxide to its intended site of action in a form active for their intended purpose. As used here, the term "NO adducts" encompasses any of such nitric oxide releasing, delivering or transferring compounds, including, for example, S-nitrosothiols, S-nitrothiols, O-nitrosoalcohols, O-nitroalcohols, sydnones, 2-hydroxy-2-nitrosohydrazines (NONOates), (E)-alkyl-2-[(E)-hydroxyimino]-5-nitro-3-

hexene amines or amides, nitrosoamines, as well as substates for the endogenous enzymes which synthesize nitric oxide. It is contemplated that any or all of these "NO adducts" can be mono- or poly-nitrosylated or nitrosated at a variety of naturally susceptible or artificially provided binding sites for nitric oxide or derivatives which donate or release NO.

One group of such NO adducts is the S-nitrosothiols, which are compounds that include at least one -S-NO group. Such compounds include S-nitroso-polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); S-nitrosylated amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); S-nitrosylated sugars, S-nitrosylated-modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides); and an S-nitrosylated hydrocarbons where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; S-nitrosylated hydrocarbons having one or more substituent groups in addition to the S-nitroso group; and heterocyclic compounds. S-nitrosothiols and the methods for preparing them are described in U.S. Patent No. 5,380,758; Oae *et al.*, *Org. Prep. Proc. Int.*, 15(3):165-198 (1983); Loscalzo *et al.*, *J. Pharmacol. Exp. Ther.*, 249(3):726729 (1989) and Kowaluk *et al.*, *J. Pharmacol. Exp. Ther.*, 256:1256-1264 (1990), all of which are incorporated in their entirety by reference.


One particularly preferred embodiment of this aspect relates to S-nitroso amino acids where the nitroso group is linked to a sulfur group of a sulfur-containing amino acid or derivative thereof. For example, such compounds include the following: S-nitroso-N-acetylcysteine, S-nitroso-captopril, S-nitroso-homocysteine, S-nitroso-cysteine and S-nitroso-glutathione.

Suitable S-nitrosylated proteins include thiol-containing proteins (where the NO group is attached to one or more sulfur group on an amino acid or amino acid derivative thereof) from various functional classes including enzymes, such as tissue-type plasminogen activator (TPA) and cathepsin B; transport proteins, such as lipoproteins, heme proteins such as hemoglobin and serum albumin; and biologically protective proteins, such as the immunoglobulins and the cytokines. Such nitrosylated proteins are




described in PCT Publ. Applic. No. WO 93/09806, published May 27, 1993. Examples include polynitrosylated albumin where multiple thiol or other nucleophilic centers in the protein are modified.



Further examples of suitable S-nitrosothiols include those having the structures:



wherein x equals 2 to 20 and  $\text{R}_e$  and  $\text{R}_f$  are as defined in this specification;



wherein x equals 2 to 20; and  $\text{R}_e$  and  $\text{R}_f$  are as defined in this specification;



wherein x equals 2 to 20;  $\text{R}_e$  and  $\text{R}_f$  are as defined in this specification; and B is selected from the group consisting of fluoro,  $\text{C}_1$ - $\text{C}_6$  alkoxy, cyano, carboxamido, cycloalkyl, arylalkoxy, alkylsulfinyl, arylthio, alkylamino, dialkylamino, hydroxy, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, amino, hydroxyl, carboxyl, hydrogen, nitro and aryl.

Nitrosothiols can be prepared by various methods of synthesis. In general, the thiol precursor is prepared first, then converted to the S-nitrosothiol derivative by nitrosation of the thiol group with  $\text{NaNO}_2$  under acidic conditions (pH is about 2.5) to yield the S-nitroso derivative. Acids which may be used for this purpose include aqueous sulfuric, acetic and hydrochloric acids. Alternatively, the precursor thiol may be nitrosylated by treatment with an alkyl nitrite such as tert-butyl nitrite.

Another group of such NO adducts are those wherein the compounds donate, transfer or release nitric oxide and are selected from the group consisting of compounds that include at least one ON-N- or ON-C- group. The compound that includes at least one ON-N- or ON-C- group is preferably selected from the group consisting of ON-N- or ON-C-polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); ON-N- or ON-C-amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures); ON-N- or ON-C-sugars; ON-N- or ON-C-

modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200, nucleotides), ON-O-, ON-N- or ON-C-hydrocarbons which can be branched or unbranched, saturated or unsaturated aliphatic hydrocarbons or aromatic hydrocarbons; ON-N- or ON-C- hydrocarbons having one or more substituent groups in addition to the ON-N- or ON-C- group; and ON-N- or ON-C-heterocyclic compounds.

Another group of such NO adducts is the nitrites which have an -O-NO group wherein the organic template to which the nitrite group is appended is a protein, polypeptide, amino acid, carbohydrate, branched or unbranched and saturated or unsaturated alkyl, aryl or a heterocyclic compound. A preferred example is the nitrosylated form of isosorbide. Compounds in this group form S-nitrosothiol intermediates *in vivo* in the recipient human or other animal to be treated and can therefore include any structurally analogous precursor R-O-NO of the S-nitrosothiols described above.

Another group of such adducts are nitrates which donate, transfer or release nitric oxide and are selected from the group consisting of compounds that include at least one at least one O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C- group. Preferred among these are those selected from the group consisting of O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C-polypeptides; O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C-amino acids; O<sub>2</sub>N-O-, O<sub>2</sub>N-N- O<sub>2</sub>N-S- or O<sub>2</sub>N-C-sugars; O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C-modified and unmodified oligonucleotides; O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C- hydrocarbons which can be branched or unbranched, saturated or unsaturated aliphatic hydrocarbons or aromatic hydrocarbons; O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C- hydrocarbons having one or more substituent groups in addition to the O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C-group; and O<sub>2</sub>N-O-, O<sub>2</sub>N-N-, O<sub>2</sub>N-S- or O<sub>2</sub>N-C-heterocyclic compounds. Preferred examples are isosorbide dinitrate and isosorbide mononitrate.

Another group of such NO adducts is the nitroso-metal compounds which have the structure (R)<sub>n</sub>-A-M(NO)<sub>n</sub>. R includes polypeptides (the term "polypeptide" includes proteins and also polyamino acids that do not possess an ascertained biological function, and derivatives thereof); amino acids (including natural and synthetic amino acids and their stereoisomers and racemic mixtures and derivatives thereof); sugars; modified and unmodified oligonucleotides (preferably of at least 5, and more particularly 5-200,

nucleotides); and a hydrocarbon where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon, or an aromatic hydrocarbon; hydrocarbons having one or more substituent groups in addition to the A-nitroso group; and heterocyclic compounds. A is S, O, or N, u and v are each integers independently selected from 1, 2 and 3, and M is a metal, preferably a transition metal. Preferred metals include iron, copper, manganese, cobalt, selenium and ruthenium. Also contemplated are N-nitrosylated metal centers such as nitroprusside.

Another group of such adducts are 2-hydroxy-2-nitrosohydrazines which donate, transfer or release nitric oxide and have a  $R_{61}R_{62}-N(O-M^+)-NO$  group wherein  $R_{61}$  and  $R_{62}$  include polypeptides, amino acids, sugars, modified and unmodified oligonucleotides, hydrocarbons where the hydrocarbon can be a branched or unbranched, and saturated or unsaturated aliphatic hydrocarbon or an aromatic hydrocarbon, hydrocarbons having one or more substituent groups and heterocyclic compounds.  $M^+$  is a metal cation, such as, for example, a Group I metal cation.

Another group of such adducts are thionitrates which donate, transfer or release nitric oxide and have the structure  $R_{61}-S-NO_2$  wherein  $R_{61}$  is as described above.

Compounds that stimulate endogenous synthesis of NO or EDRF *in vivo* include L-arginine, the substrate for nitric oxide synthase, cytokines, adenosine, bradykinin, calcitriol, bisacodyl, phenolphthalein, and endothelin.

When administered *in vivo*, the nitric oxide may be administered in combination with pharmaceutical carriers and in dosages described herein.

The nitrosated or nitrosylated compounds of the invention are used at dose ranges and over a course of dose regimen and are administered in the same or substantially equivalent vehicles/carrier by the same or substantially equivalent oral or nasal inhalant devices as their non-nitrosated or non-nitrosylated counterparts. The nitrosated or nitrosylated compounds of the invention can also be used in lower doses and in less extensive regimens of treatment. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the preferred dosage regimen set forth above.

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from about 1 to about 100 mg/kg body weight daily and more usually about 3 to 30 mg/kg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds which are known to be effective against the specific disease state targeted for treatment. The compositions of the invention can also be administered as described above or can be made to include one or more additional active compounds which are known to be effective against the specific disease state is targeted for treatment.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

These and other aspects of the present invention will be apparent to those skilled in the art from the teachings herein.

### Example 1

#### 2,6-bis(diethyl-3-methyl-3(nitrosothio)butyric acid ester)amino)-4,8-dipiperidinopyrimido-[5,4-d]-pyrimidine

##### 1a. 3-Methyl-3(2,4,6-trimethoxyphenylmethylthio)butyric acid

To a solution of 3-mercapto-3-methylbutyric acid (B.J. Sweetman et al. *J. Med Chem.*, **14**, 868 (1971)) (4.6 g, 34 mmol) in methylene chloride (250 mL) under nitrogen and cooled over ice/salt to 5 °C (internal temperature) was added trifluoroacetic acid (82 g, 0.72 mol). No significant temperature rise was noted during the addition. To this was then added dropwise a solution of 2,4,6-trimethoxybenzyl alcohol (M.C. Munson et al., *J. Org. Chem.*, **57**, 3013 (1992)) (6.45 g, 32 mmol) in methylene chloride (150 mL) such that the reaction temperature does not rise above 5 °C. After the addition was complete, the mixture was stirred for an additional 5 min at 5 °C and the volatiles were removed *in vacuo* (toluene or ethyl acetate can be used to assist in the removal of volatile material). The residue was partitioned between diethyl ether and water and the organic phase dried over anhydrous sodium sulfate, filtered and the volatile material removed *in vacuo*. The residue was treated with activated charcoal and recrystallised from diethyl ether/hexane. The product was isolated as a white solid in 70% yield (7 g) mp 103-105 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.12 (s, 2H), 3.80-3.85 (m, 11 H), 2.74 (s, 2H), 1.47 (s, 6H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 173.9, 160.6, 158.6, 105.6, 90.5, 55.7, 55.3, 45.9, 43.6, 28.4, 21.0.

##### 1b. 2,6-bis(diethyl-3-methyl-3(2,4,6-trimethoxyphenylmethylthio)butyric acid ester)amino)-4,8-dipiperidinopyrimido-[5,4-d]-pyrimidine

Under a nitrogen atmosphere, dipyrindamole (1.50 g, 2.97 mmol) was dissolved in anhydrous dimethylformamide (30 mL) and 4-dimethylaminopyridine (1.46 g, 11.9 mmol) was added, followed by the product of Example 1a (3.64 g, 11.9 mmol) and EDAC (2.28 g, 11.9 mmol). The resulting mixture was stirred 44 hours at 50 °C. The solvent was evaporated *in vacuo* and, residue was partitioned between methylene chloride and water, washed with brine and dried over anhydrous sodium sulfate. Volatiles were evaporated and the residue was purified by flash chromatography on silica gel, eluting with hexane/ ethyl acetate (2:1) to (1:1) to give the title compound

(1.02 g, 23 % yield).  $^1\text{H}$ NMR ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  1.45 (s, 24 H), 1.58-1.69 (m, 12 H), 2.70 (s, 8 H), 3.64-3.88 (m, 52 H), 4.02-4.06 (m, 8 H), 4.25-4.32 (m, 8 H), 6.10 (s, 8H).

1c. 2,6-bis(diethyl-3-methyl-3-mercaptobutyric acid ester)amino)-4,8-dipiperidinopyrimido-[5,4-d]-pyrimidine

The product of Example 1b (1.00 g, 0.63 mmol) was dissolved in methylene chloride (5.5 mL) and anisole (4.0 mL, 36.9 mmol), phenol (0.400 g, 4.25 mmol), water (4.0 mL) and trifluoroacetic acid (16 mL, 208 mmol) were added. After 1 hour 30 minutes of stirring at room temperature, toluene (5 mL) was added and volatiles were evaporated. The residue was purified by flash chromatography on silica gel eluting with hexane/ ethyl acetate (5:1) to (3:1) to give the title compound (0.360 g, 59 % yield).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  1.47 (s 24 H), 1.68-1.72 (m, 12 H), 2.29 (s, 4H), 2.63 (s, 8 H), 3.85-3.92 (m, 8 H), 3.97-4.03 (m, 8 H), 4.28-4.35 (m, 8H).

1d. 2,6-bis(diethyl-(3-methyl-3(nitrosothio)butyric acid ester)amino)-4,8-dipiperidinopyrimido-[5,4-d]-pyrimidine

The product of Example 1c (0.353 g, 0.36 mmol) was dissolved in acetic acid (20 mL) and 1N solution of hydrochloric acid (3.5 mL) was added, followed by 1 N sodium nitrite solution (2.2 mL). After 30 minutes stirring at room temperature, the reaction mixture was lyophilized, the residue was suspended in methylene chloride and washed with water, brine, and dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo and the residue was purified by flash chromatography on silica gel eluting methylene chloride/methanol (12:1) to give the title compound (0.144 g, 37 % yield). ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  1.52-1.73 (m, 12 H), 1.98 (s, 24 H), 3.20-3.38 (m, 8 H), 3.39-3.92 (m, 12 H), 3.94-4.35 (m, 12 H).

## Example 2

1-[4-[(1,3-benzodioxol-5-yl)methyl]amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic ethyl-(3-methyl-3(nitrosothio)butyramide) thioester hydrochloride

2a. 3-Methyl-3(thioacetyl)butyric acid

To a solution of 3-mercapto-3-methylbutyric acid (B.J. Sweetman et al. *J. Med Chem.*, 14, 868 (1971)) (1.03 g, 7.7 mmol) in pyridine (1.6 mL) was added acetic anhydride

(1.57 g, 15.4 mmol) and the reaction mixture was stirred at room temperature over night. The reaction mixture was slowly added to a 0 °C solution of 1 N HCl (20 ml) then water (10 ml) was added and the reaction mixture was stirred at room temperature for 2 hours. The solution was extracted with diethyl ether and the organic phase was washed with brine and then dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo and the residue was purified by flash chromatography on silica gel eluting with ethyl acetate/hexane (1:4) to give the title compound (0.791 g, 58 % yield). (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.55 (s, 6 H), 2.25 (s, 3H), 2.99 (s, 2H).

2b. Mecaptoethyl-3-Methyl-3(thioacetyl)butyramide

The product of Example 2a (0.556 g, 3.1 mmol) was dissolved in methylene chloride (10 ml) containing a catalytic amount of dimethylformamide (10  $\mu$ l). Oxalyl chloride (0.556 g, 4.4 mmol) was added and the reaction mixture was stirred at room temperature for 1 hour. The volatile components were then evaporated in vacuo and the residue azeotroped with toluene (2 x 5 ml). The yellow oil remaining was added to a -78 °C solution of 2-aminoethanethiol hydrochloride (0.341 g, 3.0 mmol), and triethylamine (0.303 g, 3.0 mmol) in dimethylformamide (6 ml). The reaction mixture was stirred at -78 °C for 1 hour and then at room temperature for 2 hours. The reaction was quenched with water (20 ml) and then extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and then concentrated in vacuo to afford the title compound (0.349 g, 53 % yield) which was used without further purification. (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.5 (s, 6 H), 2.3 (s, 3 H), 2.6 (dd, 2 H), 2.8 (s, 2 H), 2.9 (s, 1 H), 3.4 (dd, 2 H), 6.0 (brs, 1H).

2c. Mecaptoethyl-3-Methyl-3(mercapto)butyramide

The product of Example 2b (0.314 g, 1.4 mmol) was dissolved in methanol (10 ml) and solid sodium hydroxide (85 mg, 2.1 mmol) was added. After stirring 5 minutes, the reaction mixture was diluted with ethyl acetate (50 ml) and washed with saturated aqueous sodium bicarbonate, followed by brine, and then dried over anhydrous sodium sulfate. The volatile components were evaporated in vacuo leaving the title compound as a colorless oil (0.188 g, 75 % yield) which was used without further purification. (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.42 (s, 6 H), 1.55 (s, 1 H), 2.17 (s, 1 H), 2.41 (s, 2 H), 2.61 (dd, J = 12.5 Hz, 6.2 Hz, 2H), 3.39 (dd, J = 12.5 Hz, 6.2 Hz, 2H).

2d. 4-[(1,3-benzodioxol-5-ylmethyl)amino]-2,6-dichloroquinazoline

A solution of 2,4,6-trichloroquinazoline (0.186 g, 0.80 mmol) in ethanol (20 mL) was heated to 55 °C and piperonylamine (0.145 g, 0.96 mmol) was added. The resulting mixture was stirred at 55 °C overnight. Volatiles were evaporated and the residue was partitioned between methylene chloride and saturated solution of ammonium hydroxide. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to yield 0.268 g (96 % yield) of the title compound as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO) δ 4.59-4.63 (d, 2 H), 5.98 (s, 2 H), 6.86 (s, 2 H), 6.96 (s, 1 H), 7.62-7.66 (d, 1 H), 7.79-7.84 (d, 1 H), 8.46 (s, 1 H), 9.24-9.28 (t, 1 H).

2e. 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid ethyl ester

The product of Example 2d (0.164 g, 0.47 mmol) and ethyl isonipicotate (0.200 mmol, 1.27 mmol) were combined in 5 g of phenol. The resulting mixture was heated at reflux temperature (240 °C) for 5 hours. The mixture was allowed to cool down, dissolved in 20 ml of chloroform and washed with 1N solution of sodium hydroxide (250 mL). The organic fraction was dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography on silica gel, eluting with hexane/ethyl acetate (9:1) to (5:1) to give 0.164 g (53 % yield) of the title compound as a solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.24-1.30 (t, 3 H), 1.70-1.79 (m, 2 H), 1.96-2.06 (m, 2 H), 2.54-2.58 (m, 1 H), 3.01-3.10 (t, 2 H), 4.10-4.20 (q, 2 H), 4.66-4.70 (d, 2 H), 4.77-4.84 (d, 2 H), 5.59 (s, 1 H), 5.97 (s, 2 H), 6.77-6.89 (m, 3 H), 7.40-7.45 (m, 3 H).

2f. 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic acid

The product of Example 2e (0.100 g, 0.21 mmol) was dissolved in ethanol (1 mL) and water (0.5 mL) was added, followed by sodium hydroxide (0.082 g, 2.05 mmol). The resulting mixture was heated at 100 °C for 20 minutes. The volatiles were evaporated, the residue was diluted with water (2 mL) and 1N HCl was added until the pH of the reaction mixture registered pH 7. The reaction mixture was then filtered and the precipitate was washed with water (2 mL). Ethanol was added to the precipitate and the volatiles were evaporated to give 0.080 g (86 % yield) of the title compound as a pale



yellow solid.  $^1\text{H}$  NMR (300 MHz, DMSO)  $\delta$  1.36-1.45 (m, 2 H), 1.75-1.83 (m, 2 H), 2.92-3.02 (m, 3 H), 4.54-4.60 (m, 4 H), 5.94 (s, 2 H), 6.83 (s, 2 H), 6.93 (s, 1 H), 7.21-7.26 (d, 1 H), 7.44-7.49 (d, 1 H), 8.13 (s, 1 H), 8.51-8.53 (t, 1 H).

2g. 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic ethyl-(3-methyl-3(thioacetyl)butyramide) thioester

Under a nitrogen atmosphere, the product of Example 2f (0.147 g, 0.31 mmol) and triethylamine (0.043 mL, 0.31 mmol) were combined in 3 mL of DMF and heated to 50  $^{\circ}\text{C}$  to dissolve all solid. A solution of 2c (0.067 g, 0.38 mmol) in DMF (2 mL) was added, followed by EDAC (0.073 g, 0.38 mmol) and DMAP (0.015 g, 0.12 mmol). The resulting mixture was stirred at room temperature for 5 hours and then at 50  $^{\circ}\text{C}$  overnight. The reaction mixture was diluted with water (20 mL) and extracted with dichloromethane. The combined organic phase was washed with brine and dried over anhydrous sodium sulfate. The volatiles were evaporated and the residue was purified by flash chromatography on silica gel eluting with hexane/ethyl acetate (1:2) to give 0.038 g (21 % yield) of the title compound.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$ : 1.48 (s, 6 H), 1.64-1.75 (m, 2 H), 1.94-2.00 (m, 2 H), 2.04 (s, 1 H), 2.45 (s, 2 H), 2.70-2.77 (m, 1 H), 2.91-2.96 (t, 2 H), 3.01-3.08 (t, 2 H), 3.42-3.48 (t, 2 H), 4.64-4.68 (d, 2 H), 4.87-4.94 (d, 2 H), 5.64-5.68 (m, 1 H), 5.96 (s, 2 H), 6.17-6.20 (m, 1 H), 6.75-6.85 (m, 3 H), 7.38-7.45 (m, 3 H).

2h. 1-[4-[(1,3-benzodioxol-5-yl(methyl)amino)-6-chloro-2-quinazolinyl]-4-piperidine-carboxylic ethyl-(3-methyl-3(nitrosothiol)butyramide) thioester hydrochloride

The product of Example 2g (0.034 g, 0.057 mmol) was dissolved in methanol/dichloromethane (1 mL, 1:1) and 4N HCl in ether (0.100 mL) was added. Concentration in vacuo afforded a white solid. The white solid was then dissolved in a mixture of methylene chloride (3 mL) and methanol (1 mL), and the resulting solution was cooled to 0  $^{\circ}\text{C}$ . Tert-butyl nitrite (0.034 mL, 0.29 mmol) was added and the reaction mixture was stirred at 0  $^{\circ}\text{C}$  for 30 minutes. The volatiles were evaporated to give 0.037 g (98 % yield) of the title compound as a green solid.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  1.61-1.76 (m, 4 H), 1.99 (s, 6 H), 2.66-2.85 (m, 1 H), 2.90-3.04 (m, 2 H), 3.18-3.45 (m, 4 H), 3.48 (s, 2 H), 4.59-4.86 (m, 4 H), 5.87 (s, 2 H), 6.62-6.71 (d, 1 H), 6.74 (s, 1 H), 6.80-6.88 (d, 1 H), 6.90 (s, 1 H), 7.48-7.56 (m, 1 H), 7.65-7.76 (m, 1 H), 8.14-8.19 (d, 1 H), 8.43 (s, 1 H).

### Example 3

#### In Vitro Comparative Relaxation Responses

Human corpus cavernosum tissue biopsies were obtained at the time of penile prosthesis implantation from impotent men. The tissue was maintained in a chilled Krebs-bicarbonate solution prior to assay. The tissue was cut into strips of 0.3 x 0.3 x 1 cm and suspended in organ chambers for isometric tension measurement. Tissues were incrementally stretched until optimal isometric tension for contraction was obtained. Once this was achieved, the tissues were contracted with phenylephrine ( $7 \times 10^{-7}$  M) and once a stable contraction was achieved, the tissues were exposed to either dipyridamole or Example 1 ( $10^{-6}$  to  $3 \times 10^{-5}$  M) by cumulative additions to the chamber. At the end of the experiment papaverine ( $10^{-4}$  M) is added to obtain maximal relaxation. Figure 40 shows that the compound of Example 1 at doses of 10  $\mu$ M and 30  $\mu$ M is more efficacious in relaxing the phenylephrine-induced contraction than is an equimolar dose of the phosphodiesterase inhibitor dipyridamole. Data are expressed as the percent loss in tone from the phenylephrine-induced contraction (0% = phenylephrine contraction; -100% = tone after the administration of papaverine).